Knight Therapeutics Inc. (TSE:GUD - Free Report) - Equities researchers at Raymond James Financial increased their FY2025 earnings per share (EPS) estimates for Knight Therapeutics in a research note issued to investors on Wednesday, June 18th. Raymond James Financial analyst M. Freeman now forecasts that the company will earn $0.15 per share for the year, up from their previous forecast of $0.14. The consensus estimate for Knight Therapeutics' current full-year earnings is $0.10 per share. Raymond James Financial also issued estimates for Knight Therapeutics' Q1 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at $0.07 EPS.
Several other research analysts have also issued reports on the stock. Stifel Nicolaus increased their target price on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Canaccord Genuity Group set a C$6.50 target price on shares of Knight Therapeutics and gave the stock a "buy" rating in a research note on Friday, May 9th. Finally, Research Capitl raised shares of Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 11th. Two investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Strong Buy" and a consensus price target of C$7.15.
Get Our Latest Report on Knight Therapeutics
Knight Therapeutics Trading Up 0.2%
Shares of Knight Therapeutics stock traded up C$0.01 on Thursday, reaching C$5.85. 26,608 shares of the company's stock were exchanged, compared to its average volume of 68,358. The company has a market capitalization of C$591.73 million, a P/E ratio of -19.53, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 52 week low of C$5.09 and a 52 week high of C$6.45. The firm's 50-day moving average is C$5.87 and its two-hundred day moving average is C$5.70. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36.
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Further Reading
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
